1 BRIDGE PLAZA, SUITE 275, FORT LEE, NJ
Announces Pricing of $100 Million Public Offering of Common Stock
Other Events
Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In-Class Clinical-Stage Compounds
Correction of Outstanding Shares at Nuvectis Pharma's Annual Meeting
Reports First Quarter 2026 Financial Results and Business Highlights
Reports 2025 Financial Results and Business Highlights
Reports Third Quarter 2025 Financial Results and Business Highlights
Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
SEC Staff Correspondence
S-1MEF